The scoping study notes the location as being something still under consideration.
With both EGR and RNU having managed to get conditional export Australia funding (and significant sum's at US$40m and A$185m), what is the probability of E25 following that same path - major project status then Export Australia funding?
- Major Pro's - Reduced shareholder dilution to fund the project. Recognition as an important project nationally for Australia
- Major Con's - Site locations are restricted to Australia. Possibly more red tape to get through to secure the funding.
https://business.gov.au/grants-and-programs/major-project-status/current-major-projects
One of the previous barrier's to applying was needing to supply cost estimates from feasibility studies. E25 didn't have a feasibility study. E25 now got a scoping study and a feasibility study is in the works. The capital cost threshold of A$50m is clearly met at circa A$200m capital cost. Export benefits, Jobs etc would all be met from an Australian location.
- Forums
- ASX - By Stock
- E25
- Ann: Scoping Study - HPMSM Conversion Plant Economics
E25
element 25 limited
Add to My Watchlist
4.44%
!
21.5¢

Ann: Scoping Study - HPMSM Conversion Plant Economics, page-56
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
21.5¢ |
Change
-0.010(4.44%) |
Mkt cap ! $49.15M |
Open | High | Low | Value | Volume |
22.5¢ | 22.5¢ | 21.5¢ | $7.969K | 36.68K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 27140 | 21.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.5¢ | 70231 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 7664 | 0.220 |
6 | 50441 | 0.215 |
2 | 5119 | 0.210 |
3 | 338235 | 0.205 |
8 | 89405 | 0.200 |
Price($) | Vol. | No. |
---|---|---|
0.225 | 99266 | 3 |
0.230 | 72958 | 1 |
0.235 | 125765 | 4 |
0.240 | 256549 | 4 |
0.245 | 21276 | 1 |
Last trade - 12.45pm 27/06/2025 (20 minute delay) ? |
Featured News
E25 (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online